A selective under-condensation of the heterochromatic blocks 1qh, 9qh and 16qh was induced in normal peripheral blood lymphocyte cultures, using the DNA analogue 5-azacytidine. With 5-azacytidine at a concentration of 3.5 × 10-7 µM, phytohemagglutinin (PHA)-stimulated cultures (predominantly proliferating T lymphocytes) showed a significantly higher percentage of metaphases with under-condensation of heterochromatic blocks than pokeweed (PWM)-stimulated cultures (mainly activated B lymphocytes). When the concentration of 5-azacytidine in the culture medium was increased ten times, no significant difference was noticed between PHA- and PWM-stimulated cultures. At this higher dose, the response in PHA cultures remained the same while the response of PWM cultures increased dramatically. Thus, there is a differential in vitro relaxation of the heterochromatin condensation by 5-azacytidine, with T lymphocytes being much more sensitive than B lymphocytes.

Keywords:
Constitutive heterochromatin, 5-Azacytidine, T lymphocytes, B lymphocytes
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.